RT  - European Journal of Gynaecological Oncology
ID  - 10.12892/ejgo2672.2015
T1  - Serum human epididymis protein 4 can be a useful tumor marker in the differential diagnosis of adnexal masses during pregnancy: a pilot study
A1  - F. Gucer
A1  - G. Kiran
A1  - E. Canaz
A1  - M. Kilinc
A1  - H.C. Ekerbicer
A1  - F. Avci
A1  - H. Kiran
A1  - A. Coskun
A1  - D.C. Arikan
K1  - Cancer antigen 125; Human epididymis protein 4; Tumor markers in pregnancy.
YR  - 2015
SP  - 406
AB  - <p><i>Purpose: </i>The purpose of this study was to evaluate serum concentrations of human epididymis protein 4 (HE4) and cancer antigen 125 (CA 125) in healthy women and their pregnant counterparts to determine the influence of pregnancy on these biomarkers. <i>Materials</i><i> </i><i>and Methods: </i>Serum concentrations of CA 125 and HE4 were measured in 27 healthy non-pregnant women and 26 healthy pregnant women in the first and second trimesters. <i>Results: </i>Higher concentration of CA 125 was found in pregnants than in non-pregnant women (<i>p </i>= 0.002). There was no difference in CA 125 concentrations between first and second trimesters (<i>p </i>= 0.13). Serum HE4 concentration was not different in pregnant group compared to non-pregnant women (<i>p </i>= 0.510). Likewise, no difference was found in HE4 levels between the trimesters (<i>p </i>= 0.485). There was a positive correlation between increasing parity and CA 125 (<i>p </i>= 0.023), but not HE4 (<i>p </i>= 1.0). <i>Conclusion: </i>HE4 serum biomarker is unaffected by pregnancy status and may be useful for evaluation of doubtful pelvic masses in pregnancy. Contrarily, increased serum levels of CA 125 could yield increased number of false-positive results.</p>